AtheroGenics, Inc.{AGIX}-nasdaq Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AtheroGenics, Inc.{AGIX}-nasdaq

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Secret_Agent_Man who wrote (5)	9/6/2000 11:18:09 AM
From: Secret_Agent_Man	of 332

C O R R E C T I O N -- AtheroGenics, Inc./ In HSW012, "AtheroGenics (Nasdaq: AGIX) Announces Second Quarter Financial Results," we are advised by a representative of the company that the following verbiage accompanying the charts was incorrect: "Research and development compensation" should read, "Research and development, excluding amortization of deferred stock compensation," "General and administrative" should read, "General and administrative, excluding amortization of deferred stock compensation," Also, an asterisk was omitted after Pro Forma* net loss per share and Pro Forma* weighted average shares outstanding. The asterisk referred to the following footnote, which was also inadvertently omitted: * Pro forma net loss per share assumes conversion of all outstanding preferred stock into shares of AtheroGenics' common stock (which was effected upon the closing of AtheroGenics' initial public offering), as if such conversion had occurred on the dates of original issue. http://www.prnewswire.com (C) 2000 PR Newswire. All rights reserved.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next